Catalog No.
Product Name
Application
Product Information
Citations
-
PDE4 Inhibitor
MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor that enhances intracellular cyclic adenosine monophosphate (cAMP) levels by blocking PDE4 activity. This elevation in cAMP activates protein kinase A (PKA), which subsequently inhibits inflammatory cell activity and promotes relaxation of airway smooth muscle. MK-0873 is suitable for research applications related to chronic obstructive pulmonary disease (COPD), providing insights into potential therapeutic strategies for respiratory conditions characterized by inflammation and airway constriction. -
PDE10A Inhibitor
PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A), displaying an IC50 of 4.6 nM and an ED50 of 13 mg/kg. This compound influences patterns of brain glucose metabolism, potentially serving as a translational biomarker in neurological research. PQ-10 is particularly valuable for investigating psychiatric disorders, including schizophrenia, and provides insights into the underlying mechanisms of these conditions. -
PDE4 Inhibitor
MK-0952 is a selective phosphodiesterase 4 (PDE4) inhibitor, characterized by an IC50 value of 0.53 nM. This compound exhibits potential therapeutic effects for disorders associated with PDE4 modulation, particularly in the context of Alzheimer's disease research. MK-0952 provides a valuable tool for studying the role of PDE4 in cognitive function and neurodegenerative diseases. -
PDE4 Inhibitor
(S)-Gebr32a is a selective phosphodiesterase 4 (PDE4) inhibitor, demonstrating IC50 values of 19.5 µM for PDE4 cat and 2.1 µM for PDE4D3. It exhibits significant biological activity by modulating intracellular cyclic AMP levels, making it a valuable tool for investigating inflammatory processes and neurodegenerative diseases. This compound is suitable for research applications focused on the role of PDE4 in various cellular signaling pathways. -
PDE5 Inhibitor
Yonkenafil hydrochloride is a selective phosphodiesterase 5 (PDE5) inhibitor, known for its neuroprotective properties. It effectively reduces cerebral infarction, neurological deficits, edema, and neuronal damage following ischemic events. Additionally, Yonkenafil may enhance cognitive function through modulation of neurogenesis, suggesting its potential therapeutic applications in neurodegenerative conditions such as Alzheimer's disease. -
PDE4 Antagonist
Eggmanone is a selective antagonist of phosphodiesterase 4 (PDE4), with an IC50 of 72 nM for the PDE4D3 isoform. This compound exhibits a remarkable 40- to 50-fold selectivity for PDE4D3 over other phosphodiesterases. By inhibiting PDE4, Eggmanone activates protein kinase A, resulting in the blockade of Hedgehog (Hh) signaling pathways. This biological activity makes Eggmanone a valuable tool for research into cellular signaling and potential therapeutic applications in conditions mediated by Hh pathways. -
Phosphodiesterase (PDE)
PDE7-IN-4 is a selective inhibitor of phosphodiesterase 7 (PDE7), which enhances intracellular levels of cyclic adenosine monophosphate (cAMP). This compound demonstrates significant potential in modulating neurotransmission and exhibits anti-inflammatory effects through the cAMP/cAMP response element binding protein (CREB) signaling pathway. PDE7-IN-4 is a valuable tool for researchers investigating neurodegenerative diseases and inflammation-related conditions, offering insights into therapeutic mechanisms and potential interventions. -
Phosphodiesterase (PDE) Inhibitor
PDE10-IN-1 is a selective inhibitor of phosphodiesterase 10 (PDE10), which plays a crucial role in regulating cyclic nucleotide levels in the central nervous system. This compound has demonstrated potential in modulating dopaminergic signaling and offers promise for investigating therapeutic strategies for central nervous system and metabolic disorders. Its mechanism of action may provide insights into the treatment of various neuropsychiatric conditions. -
PDE5 Inhibitor
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor that disrupts the hydrolysis of cyclic guanosine monophosphate (cGMP) in a competitive manner, with an IC50 value of 0.23 nM. This compound also demonstrates inhibitory effects on PDE6 (IC50=56 nM) while displaying low potency against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 is valuable for research focusing on the nitric oxide (NO)/cGMP signaling pathway, with potential applications in cardiovascular and erectile dysfunction studies. -
PDE III Inhibition
Senazodan hydrochloride is a selective inhibitor of phosphodiesterase III (PDE III), functioning primarily as a calcium sensitizer. This compound enhances cardiac contractility and has potential applications in researching heart failure and other cardiovascular disorders. Its ability to modulate cAMP levels makes it a valuable tool for investigating the signaling pathways involved in cardiac function and disease. -
PDE4 Inhibitor
Denbufylline is a potent phosphodiesterase-4 (PDE4) inhibitor that effectively prevents the degradation of intracellular cyclic adenosine monophosphate (cAMP). This inhibition leads to increased levels of cAMP, which plays a crucial role in regulating various cellular functions. Denbufylline is primarily utilized in research related to chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory conditions, making it a valuable tool for understanding these complex diseases. -
PDE4B Modulator
PDE4B modulator-1 is a selective modulator of phosphodiesterase 4B (PDE4B), targeting intracellular signaling pathways. It exhibits significant inhibition of PDE4B activity, leading to increased cAMP levels and subsequent regulation of various cellular processes. This compound is valuable for research in neurobiology, inflammation, and respiratory diseases, providing insights into PDE4B's role in mediating inflammatory responses and neuronal signaling. -
Phosphodiesterase (PDE)
(E/Z)-N-Desethylsunitinib hydrochloride is a potent inhibitor of phosphodiesterase (PDE), functioning as a competitive inhibitor of ATP. This compound exhibits significant anti-tumor activity by targeting and inhibiting VEGF-R2 and PDGF-Rβ tyrosine kinases. Its role as the principal active metabolite of sunitinib makes it valuable for research applications focused on tumor angiogenesis and proliferation. -
Phosphodiesterase (PDE) Control
Sildenafil chlorosulfonyl functions as a synthetic intermediate in the production of sildenafil, a selective phosphodiesterase 5 (PDE5) inhibitor. This compound plays a crucial role in the regulation of cGMP levels, presenting significant implications for research into erectile dysfunction and pulmonary arterial hypertension. Its application in various biochemical pathways makes it a valuable reagent for studies involving PDE inhibition and the modulation of nitric oxide signaling. -
PDE-5 Inhibitor
Aildenafil, also known as Methisosildenafil, is a potent inhibitor of phosphodiesterase type 5 (PDE-5), which facilitates vasodilation by elevating nitric oxide (NO) levels. This compound is primarily utilized in research exploring cardiovascular effects and conditions related to erectile dysfunction. Its ability to enhance blood flow through the modulation of cyclic guanosine monophosphate (cGMP) levels makes it a valuable tool for studying vascular physiology and pharmacology. -
PDE4 Inhibitor
PF-07038124 is a potent phosphodiesterase 4 (PDE4) inhibitor, exhibiting an IC50 of 0.5 nM for the PDE4B2 isoform. It demonstrates significant inhibitory activity against pro-inflammatory cytokines, including IL-13 (IC50 = 125 nM), IL-4 (IC50 = 4.1 nM), and IFN-γ (IC50 = 1.06 nM). This compound is valuable for research applications related to atopic dermatitis and plaque psoriasis, offering insights into therapeutic strategies for managing these inflammatory conditions. -
PDE4 Inhibitor
LASSBio-1632 is a selective phosphodiesterase 4 (PDE4) inhibitor, specifically targeting the PDE4A and PDE4D isoenzymes. This compound demonstrates significant anti-asthmatic properties by attenuating airway hyper-reactivity and inhibiting TNF-α production in lung tissue. Additionally, LASSBio-1632 exhibits high permeability across the blood-brain barrier, facilitating its potential use in various research applications related to respiratory conditions. -
PDE1 Inhibitor
PF-04822163 is a selective phosphodiesterase 1 (PDE1) inhibitor that effectively crosses the blood-brain barrier, exhibiting IC50 values of 2 nM for PDE1A, 2.4 nM for PDE1B, and 7 nM for PDE1C. This compound demonstrates significant potential for modulating intracellular signaling pathways, making it valuable in the study of neurological disorders such as attention deficit hyperactivity disorder and Parkinson's disease. Its potency and selectivity support its use in preclinical research efforts aimed at elucidating the role of PDE1 in these conditions. -
PDE5 Inhibitor
Vardenafil dihydrochloride is a selective inhibitor of phosphodiesterase-5 (PDE5), demonstrating a potent inhibitory effect with an IC50 of 0.7 nM. It also exhibits inhibition of PDE1 and PDE6 with IC50 values of 180 nM and 11 nM, respectively, while showing minimal activity against PDE3 and PDE4. By competitively inhibiting the hydrolysis of cyclic guanosine monophosphate (cGMP), Vardenafil dihydrochloride elevates cGMP levels, making it a valuable tool for studying conditions such as erectile dysfunction, hepatitis, and diabetes. -
PDE-5 Inhibitor
Avanafil dibenzenesulfonate is a selective phosphodiesterase-5 (PDE-5) inhibitor with a potent IC50 of 5.2 nM for PDE-5, demonstrating significant selectivity against other PDE isoforms. This compound activates the NO/cGMP/PKG signaling pathway, ultimately leading to reduced bone mineral density loss, alleviation of bone atrophy, and decreased oxidative stress. Avanafil dibenzenesulfonate is suitable for research applications related to erectile dysfunction and osteoporosis, where modulation of cGMP levels is crucial. -
TbrPDEB1 Inhibitor
NPD-1335 is an inhibitor of Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1), demonstrating submicromolar efficacy against T. brucei parasites. This compound enhances intracellular cAMP levels, leading to cell cycle disruption and apoptosis in the target cells. Additionally, NPD-1335 features an alkyne moiety, enabling its use as a click chemistry reagent for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, thus expanding its utility in various research applications. -
PDE5 Inhibitor
TPN729MA is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. This compound plays a critical role in regulating erectile function and is suitable for research applications related to erectile dysfunction. Its potent inhibitory effect on PDE5 makes it a valuable tool for studying the underlying mechanisms of this condition. -
PDE5 Inhibitor
TPN729 is a selective inhibitor of phosphodiesterase type 5 (PDE5), exhibiting an IC50 value of 2.28 nM. This compound is primarily involved in modulating erectile function and serves as a valuable tool in the research of erectile dysfunction. Its high potency and specificity make it suitable for investigating PDE5's role in various physiological and pathological processes. -
PDE Inhibitor
Autotaxin-IN-4 is a potent inhibitor of autotaxin, targeting the enzyme responsible for lysophosphatidic acid production. This compound exhibits promising biological activity in the modulation of fibrosis processes, making it a candidate for research in conditions such as idiopathic pulmonary fibrosis. It serves as a valuable tool for studies aimed at understanding the role of autotaxin in fibrotic diseases and exploring therapeutic interventions. -
PDE Inhibitor
PDE1-IN-3 is a selective inhibitor of human phosphodiesterase 1 (PDE1), known for its potential to modulate intracellular cyclic nucleotide levels. This compound also demonstrates inhibitory activity against PDE4D and PDE6AB, with IC50 values of 23.99 μM and 10 μM, respectively. PDE1-IN-3 is suitable for research applications focused on cardiovascular diseases, neuroprotection, and other conditions where cyclic nucleotide signaling plays a critical role. -
PDE III Inhibitor
WIN-63291 is a selective and orally active phosphodiesterase III (PDE III) inhibitor. It effectively increases intracellular cyclic AMP levels, which plays a critical role in cardiovascular function. This compound is primarily utilized in research applications aimed at investigating cardiovascular diseases and their associated pathways. -
AR Antagonist/PDE5 Inhibitor
ID11916 is an orally active antagonist of the androgen receptor (AR) and a phosphodiesterase 5 (PDE5) inhibitor. It effectively inhibits androgen binding to AR, prevents nuclear translocation, and suppresses androgen-dependent transcriptional activity. Additionally, ID11916 elevates intracellular cGMP levels and activates protein kinase G (PKG) through its inhibitory effects. This compound demonstrates significant anti-cancer activity against prostate cancer cell lines VCaP and 22Rv1, as well as in AR-positive breast cancer cell lines such as SK-BR-3, making it a valuable tool for cancer research. -
PDE Inhibitor
Menabitan dihydrochloride is a selective inhibitor of phosphodiesterase 9 (PDE 9), demonstrating potential as a non-opioid analgesic agent. This compound has been shown to effectively reduce intraocular pressure in rabbit models, making it valuable for research in ocular health and pain management. Its specificity for PDE 9 positions it as an important tool for studies investigating the role of cyclic nucleotides in various physiological processes. -
PDE4 Inhibitor
Davalomilast is a selective phosphodiesterase 4 (PDE4) inhibitor known for its anti-inflammatory properties. This compound is of particular interest in research on autoimmune diseases and dermatological conditions, where it may modulate inflammatory responses and provide therapeutic insights. Its mechanism suggests potential applications in alleviating symptoms associated with various inflammatory disorders. -
PDE3 Inhibitor
OPC-33540 is a highly selective and competitive inhibitor of phosphodiesterase 3 (PDE3), exhibiting IC50 values of 0.32 nM for PDE3A and 1.5 nM for PDE3B. This compound demonstrates significantly reduced activity against other phosphodiesterases, with IC50 values ranging from 42.9 μM to 100.8 μM for PDE1, PDE2, PDE4, PDE5, and PDE7. OPC-33540 effectively increases cAMP levels in platelets and inhibits thrombin-induced platelet aggregation, making it a valuable tool for antithrombotic research applications. -
PDE 10 Inhibitor
Gemlapodect is a potent inhibitor of phosphodiesterase 10A (PDE10A). This compound has been shown to modulate intracellular signaling pathways and is primarily used in researching schizophrenia. Its ability to prevent the degradation of cyclic nucleotides makes it a valuable tool for studying neuropsychiatric disorders and potential therapeutic interventions. -
PDE11 Inhibitor
PDE11-IN-1 is a selective inhibitor of phosphodiesterase 11 (PDE11), a key enzyme involved in the regulation of cyclic nucleotide signaling. This compound plays a crucial role in adrenal insufficiency research by modulating intracellular cAMP and cGMP levels, which can impact adrenal hormone synthesis and secretion. PDE11-IN-1 is a valuable tool for investigating the physiological and pathophysiological processes associated with adrenal function and related disorders. -
PDE Inhibitor
5,7-Diacetoxy-8-methoxyflavone is a potent phosphodiesterase (PDE) inhibitor with a mechanism of action targeting cAMP metabolism. This compound exhibits significant biological activity by enhancing cAMP levels, thereby influencing various cellular processes. It is primarily utilized in research applications focused on cell signaling, inflammation, and potential therapeutic interventions related to PDE modulation. -
PDE Inhibitor
ER21355 hydrochloride is a potent phosphodiesterase (PDE) inhibitor that enhances levels of cyclic AMP (cAMP) and cyclic GMP (cGMP) within cells. This action facilitates the relaxation of smooth muscle cells, making it a valuable candidate for research into therapeutic strategies for benign prostatic hyperplasia (BPH) and related conditions. ER21355 hydrochloride provides a useful tool for studies focused on the modulation of smooth muscle relaxation and its implications in prostatic disorders. -
Phosphodiesterase (PDE)
Nor-Acetildenafil is a derivative of Acetildenafil and functions as a phosphodiesterase (PDE) inhibitor. This compound demonstrates biological activity that may enhance blood flow by promoting vasodilation. It is used in research applications focused on cardiovascular health and erectile dysfunction therapies, providing insights into mechanisms of action of PDE inhibitors. -
PDE-III Inhibitor
Meribendan is a potent phosphodiesterase III (PDE-III) inhibitor. It enhances intracellular cyclic adenosine monophosphate (cAMP) levels, promoting cardiac contractility and vasodilation. This compound is primarily used in cardiovascular research, providing insights into heart failure mechanisms and potential therapeutic strategies. -
PDE8B Inhibitor
PDE8B-IN-1 hydrochloride is a potent and selective inhibitor of phosphodiesterase type 8B (PDE8B) with an IC50 value of 1.5 nM. This compound is valuable for research focused on the modulation of intracellular cAMP levels, which is relevant in the study of diabetes and related metabolic disorders. PDE8B-IN-1 hydrochloride provides a useful tool for investigating the role of PDE8B in cellular signaling pathways and potential therapeutic strategies. -
PDE5 Inhibitor
Thioquinapiperifil is a potent, selective, and non-competitive inhibitor of phosphodiesterase-5 (PDE-5), with an IC50 of 0.074 nM. This compound is primarily utilized in research focusing on sexual enhancement and the modulation of erectile function. Its high specificity and efficacy make it a valuable tool for investigating PDE5-related pathways and potential therapeutic applications in sexual health. -
PDEδ Inhibitor
Deltazinone 1 is a selective phosphodiesterase δ (PDEδ) inhibitor with a KD value of 8 nM, targeting the PDEδ-Ras interaction. It demonstrates a dose-dependent inhibitory effect on the proliferation of oncogenic KRas-dependent cell lines, making it a valuable compound for studying KRas signaling pathways and potential therapeutic interventions in cancer research. -
PDE4 Inhibitor
PDE4-IN-34 is a selective phosphodiesterase 4 (PDE4) inhibitor, demonstrating IC50 values of 19 pM and 14 pM for PDE4B1 and PDE4D2, respectively. This compound shows weak inhibitory activity against PDE8A1 (IC50 of 4.092 μM) and exhibits significant selectivity over other PDE subtypes (IC50 > 10 μM). PDE4-IN-34 effectively improves pulmonary function, reduces inflammatory responses, and mitigates lung tissue damage in rat models of chronic obstructive pulmonary disease induced by cigarette smoke and LPS. It serves as a valuable tool for research into PDE4-related pathways in pulmonary disorders. -
PDE11A4 Inhibitor
PDE11A4-IN-1 is a selective inhibitor of the phosphodiesterase 11A4 (PDE11A4) enzyme, exhibiting an IC50 of 12 nM. This compound demonstrates strong selectivity for PDE11A4 compared to other phosphodiesterases including PDE1, PDE2, PDE7, PDE8, and PDE9. It is suitable for studies investigating the role of PDE11A4 in various biological processes and potential therapeutic applications in conditions influenced by cyclic nucleotide signaling. -
PDE3/4 Inhibitor
PDE3/4-IN-3 is a potent dual inhibitor of phosphodiesterase 3 and 4, exhibiting IC50 values of 0.17 nM for PDE3A and ≤50 nM for PDE4B2. This compound effectively reduces methacholine-induced bronchoconstriction in guinea pigs, demonstrating its potential in respiratory research. PDE3/4-IN-3 is valuable for investigating therapeutic strategies in chronic obstructive pulmonary disease (COPD) and asthma. -
Phosphodiesterase (PDE) Inhibitor
RA642 is a selective phosphodiesterase (PDE) inhibitor that enhances arterial blood pressure and promotes vasodilation. This compound demonstrates significant biological activity by improving cerebral blood flow and reducing both cerebrovascular and peripheral resistance. It exhibits a relaxant effect on smooth muscle, akin to that of papaverine, making it a valuable tool for studying cardiovascular dynamics and smooth muscle physiology in research settings. -
Phosphodiesterase (PDE) Inhibitor
ATX inhibitor 7 is a selective inhibitor of autotaxin, a lysophospholipase that catalyzes the production of lysophosphatidic acid (LPA) from lysophosphatidylcholine. This compound demonstrates significant oral bioavailability, making it a valuable tool for investigations into the role of LPA signaling in various physiological and pathological processes. ATX inhibitor 7 is suitable for research applications related to cancer, fibrosis, and neurodegenerative diseases, where modulation of autotaxin activity may offer therapeutic benefits. -
PDE5 Inhibitor
T-1032 free base is a highly selective phosphodiesterase 5 (PDE5) inhibitor, exhibiting an IC50 value of 1.0 nM. It demonstrates a significant relaxant effect on isolated rabbit corpus cavernosum. T-1032 free base is primarily utilized in research focused on erectile dysfunction and related vascular disorders. -
PDE Inhibitor
Imazodan hydrochloride is a selective phosphodiesterase III (PDE III) inhibitor that enhances myocardial contractility by preventing the degradation of cyclic adenosine monophosphate (cAMP). This compound improves cardiac contractile function and serves as a peripheral vasodilator. Imazodan hydrochloride is relevant for research applications involving cardiovascular conditions and the modulation of heart function. -
PDE Inhibitor
Isopedicin is a potent phosphodiesterase (PDE) inhibitor that effectively reduces superoxide anion (O2•-) production in formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)-activated cells. By inhibiting PDE activity, Isopedicin enhances cyclic AMP (cAMP) formation and promotes protein kinase A (PKA) activity, thereby influencing various intracellular signaling pathways. This compound is suitable for research applications investigating oxidative stress and signaling mechanisms in immune responses. -
PDE2A Inhibitor
PDE2A-IN-2 is a selective inhibitor of phosphodiesterase type 2A (PDE2A) with a Ki value of 5.49 nM, demonstrating over 100-fold selectivity against other PDE isoforms. This compound serves as a radiolabeled PET tracer, facilitating brain imaging in patients with neurodegenerative diseases by eliciting a signal specifically in PDE2A-rich regions. Its application in neurodegenerative disease research highlights its potential in studying PDE2A's role in pathophysiology. -
PDE5 Inhibitor
(R)-Xanthoanthrafil is a selective phosphodiesterase-5 (PDE5) inhibitor. By increasing cyclic guanosine monophosphate (cGMP) levels, it promotes smooth muscle relaxation, facilitating penile erection. This compound is valuable for research applications related to erectile dysfunction and the physiological mechanisms governing this condition. -
PDE4 Inhibitor
Z21090 is a selective inhibitor of phosphodiesterase-4 (PDE4), exhibiting an IC50 value of 37.4 nM and demonstrating oral bioavailability. This compound is significant for studies related to alcohol-related diseases and offers potential therapeutic insights into inflammatory processes and neurodegenerative conditions associated with PDE4 activity. Researchers may utilize Z21090 to explore its effects on cyclic AMP signaling pathways and related biological mechanisms.
